Ország: Ausztrália
Nyelv: angol
Forrás: Department of Health (Therapeutic Goods Administration)
Finasteride
Pharmacor Pty Ltd
Finasteride
FINASTERIDE-GA 5 CONSUMER MEDICINE INFORMATION Version3.0 PAGE 1 OF 4 SEPT 2010 - FINASTERIDE-GA 5 Finasteride Tablets 5 mg CONSUMER MEDICINE INFORMATION _WHAT _ _IS _ _IN _ _THIS _ _LEAFLET _ This leaflet answers some common questions about Finasteride-GA 5 . It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Finasteride-GA 5 against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. _WHAT _ _FINASTERIDE-GA _ _5 IS USED FOR _ Finasteride-GA 5 is for use by men only. Finasteride-GA 5 is used to treat a medical condition in men called benign prostatic hyperplasia or BPH. BPH is a condition where your prostate gland (which is near your bladder) has become bigger making it more difficult for you to pass urine. This can lead to symptoms such as: Weak or interrupted stream of urine Feeling that you cannot empty your bladder completely A delay before you start to pass urine Needing to pass urine often, especially at night Feeling that you must pass urine right away BPH occurs only in men and is common over the age of 50 years. In some men, BPH can lead to serious problems, including urinary tract infections and the sudden inability to pass urine at all. BPH can also lead to the need for surgery such as procedures to improve the flow of urine. The prostate gland takes years to grow. Therefore, the symptoms of BPH take a long time to develop. Finasteride- GA 5 works by slowly reducing the size of your prostate gland. This may lead to gradual improvement in your urine flow and other symptoms over several months. Finasteride-GA 5 also helps reduce the risk of developing a sudden inability to pass urine (acute urinary retention) and the need for surgery. This may happen whether or not you notice any improve Olvassa el a teljes dokumentumot
Product Information: Fi nasteride-GA 5 (Finasteride Film-coated Tablets 5 mg) Ver 3.0 PAGE 1 OF 11 SEPT 2010- PRODUCT INFORMATION FINASTERIDE-GA 5 (FINASTERIDE FILM-COATED TABLETS 5 MG) NAME OF THE MEDICINE Finasteride is described chemically as: _N-_(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β- carboxamide. The CAS No is 98319-26-7. The empirical formula is C 23 H 36 N 2 O 2 and the molecular weight is 372.55. The structural formula is: DESCRIPTION Finasteride is a white, crystalline solid. It is freely soluble in chloroform and in lower alcohol solvents, but is practically insoluble in water. COMPOSITION ACTIVE: Finasteride INACTIVES: Lacto se, cellulose microcrystalline, pregelatinised starch, lauroyl macrogolglycerides, sodium starch glycollate, magnesium stearate and Opadry 03F20404 Blue. PHARMACOLOGY MECHANISM OF ACTION Finasteride is a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor. CLINICAL PHARMACOLOGY Benign prostatic hyperplasia (BPH) occurs in the majority of men over the age of 50 and its prevalence increases with age. Epidemiologic studies suggest that enlargement of the prostate gland Product Information: Fi nasteride-GA 5 (Finasteride Film-coated Tablets 5 mg) Ver 3.0 PAGE 2 OF 11 SEPT 2010- is associated with a 3-fold increase in the risk of acute urinary retention and prostate surgery. Men with enlarged prostates are also 3 times more likely to have moderate to severe urinary symptoms or a decrease in urinary flow than men with smaller prostates. The development and enlargement of the prostate gland and subsequent BPH is dependent upon the conversion of testoste Olvassa el a teljes dokumentumot